Lymphodepletion: systemic chemotherapy with acute toxicities and detrimental long-term consequences for anti-tumor immune function
Umoja’s RACR technology drives Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs, a proprietary and uniquely scalable process for manufacturing potent and persistent engineered immune effector cells
